Dhavalkumar Patel
Chief Tech/Sci/R&D Officer bij UCB
Oorsprong van het eerstegraads netwerk van Dhavalkumar Patel
| Entiteit | Type entiteit | Industrie | |
|---|---|---|---|
The University of North Carolina at Chapel Hill
119
| College/University | Other Consumer Services | 119 |
35
| Public Company | Pharmaceuticals: Major | 35 |
Novartis International AG
 Novartis International AG Pharmaceuticals: MajorHealth Technology Novartis International AG manages the Novartis Group. It provides administrative, financial, legal, and technical services. It also offers scientific consultation to the Group. The company was founded on December 13, 1989 and is headquartered in Basel, Switzerland.
27
| Subsidiary | Pharmaceuticals: Major | 27 |
| Subsidiary | Pharmaceuticals: Major | 20 | |
Duke University Medical Center
14
| College/University | Other Consumer Services | 14 |
Anokion SA
 Anokion SA Medical/Nursing ServicesHealth Services Anokion SA provides technology for retraining white blood cells to induce therapeutic immune tolerance. The firm?s approach to antigen-specific immune tolerance can be translated to virtually any protein in numerous clinical indications. The company was founded by Jerffery Hubbell, Melody Swartz, Stephan Kontos, Oscar Buset, Kristen M. Lorentz and David A. Lowin and is headquartered in Ecublens, Switzerland.
13
| Holding Company | Medical/Nursing Services | 13 |
Priothera Ltd.
 Priothera Ltd. BiotechnologyHealth Technology Priothera Ltd. engages in the development of orally delivered sphingosine-1-phosphate (S1P) receptor modulators for hematological malignancies. The company was founded by Florent Gros, Shaval Patel, and Brice Suire in 2020 and is headquartered in Dublin, Ireland.
8
| Holding Company | Biotechnology | 8 |
Kanyos Bio, Inc.
 Kanyos Bio, Inc. Pharmaceuticals: MajorHealth Technology Kanyos Bio, Inc. engages in the provision of immune tolerance technology solutions. It develops antigen-specific for treatment of type-1 diabetes and celiac disease. The company was founded by Jeffrey Hubbell, Stephan Kontos, Oscar Buset, Kristen M. Lorentz, and David A. Lowin in 2015 and is headquartered in Cambridge, MA.
8
| Subsidiary | Pharmaceuticals: Major | 8 |
Quell Therapeutics Ltd.
 Quell Therapeutics Ltd. Pharmaceuticals: MajorHealth Technology Quell Therapeutics Ltd. is a London-based biotechnology company, which develops immune cell therapies to target transplant rejection, autoimmune and inflammatory diseases. It develops engineered T regulatory cell therapies for a variety of non-cancer targets. The company was founded on March 19, 2019 and is headquartered in London, the United Kingdom.
6
| Holding Company | Pharmaceuticals: Major | 6 |
Inflazome Ltd.
 Inflazome Ltd. Pharmaceuticals: MajorHealth Technology Inflazome Ltd. engages in developing therapeutic medicines for inflammatory diseases. It manufactures and supplies medicines for muckle wells, type 2 diabetes, atherosclerosis, hypertension, gout, osteoarthritis, rheumatoid arthritis, Parkinson, Alzheimer, and multiple sclerosis. The company was founded by Matthew A. Cooper and Luke O'Neill in 2016 and is headquartered in Dublin, Ireland.
4
| Subsidiary | Pharmaceuticals: Major | 4 |
Grafiek van bedrijven verbonden in de tweede graad
Connectie in verschillende bedrijven
Bedrijven verbonden met Dhavalkumar Patel via zijn persoonlijke netwerk
| Onderneming | Sector | Gelieerde personen | Hoofdpost |
|---|---|---|---|
| ELI LILLY AND COMPANY | Pharmaceuticals: Major | Corporate Officer/Principal Sales & Marketing Corporate Officer/Principal | |
MedImmune LLC
 MedImmune LLC BiotechnologyHealth Technology MedImmune LLC develops medicines for the prevention and treatment of infectious diseases such as cancer and immune system disorders. It offers solutions in the areas of monoclonal antibodies and vaccines for infection, oncology, respiratory disease and inflammation, cardiovascular diseases, and neuroscience. The company was founded by Wayne T. Hockmeyer in 1988 and is headquartered in Gaithersburg, MD. | Biotechnology | Director/Board Member Director of Finance/CFO | |
| BIOGEN INC. | Pharmaceuticals: Major | Director of Finance/CFO Corporate Officer/Principal | |
| MERCK KGAA | Pharmaceuticals: Major | Chief Executive Officer Chief Investment Officer General Counsel | |
International Federation of Pharmaceutical Manufacturers
 International Federation of Pharmaceutical Manufacturers BiotechnologyHealth Technology The International Federation of Pharmaceutical Manufacturers and Traders is a global organization that promotes technology transfer in the pharmaceutical industry. The non-profit company is based in Geneva, Switzerland. The Swiss company believes that technology transfer helps bridge research and development gaps, increases the availability of vaccines and medicines, and stimulates investment in key industrial areas. David Reddy has been the CEO of the company since 2024. | Biotechnology | Director/Board Member Corporate Officer/Principal President | |
| TETRAPHASE PHARMACEUTICALS, INC. | Pharmaceuticals: Major | Director of Finance/CFO Corporate Officer/Principal | |
Biotechnology Innovation Organization
 Biotechnology Innovation Organization Miscellaneous Commercial ServicesCommercial Services Biotechnology Innovation Organization is the world's biotechnology organization, providing advocacy, business development and communications services for more than 1,200 members worldwide. BIO members are involved in the research and development of innovative healthcare, agricultural, industrial and environmental biotechnology technologies. Corporate members range from entrepreneurial companies developing a first product to Fortune 100 multinationals. also represent state and regional biotech associations, service providers to the industry and academic centers. | Miscellaneous Commercial Services | Director/Board Member Director/Board Member Director/Board Member | |
| FLEXION THERAPEUTICS, INC. | Pharmaceuticals: Major | Corporate Officer/Principal Chief Executive Officer | |
| NOVARTIS AG | Pharmaceuticals: Major | Chief Executive Officer Sales & Marketing Corporate Officer/Principal Corporate Officer/Principal | |
Goldman Sachs & Co. LLC
 Goldman Sachs & Co. LLC Financial ConglomeratesFinance Goldman Sachs & Co. LLC (GS&Co.) is a securities brokerage firm headquartered in New York City. Founded in 1927, the firm is a subsidiary of The Goldman Sachs Group, Inc. (NYSE: GS). GS&Co. provides services to help hedge funds manage risk, monitor portfolios, maintain liquidity and build their businesses. They offer clients access to global equity and derivatives markets, as well as foreign exchange, commodities, European Lefts, rates and credit across the Americas, Europe and Asia. The firm proactively monitors capital markets, searching for pockets of liquidity and news that may require changes to those strategies. Integration with the Goldman Sachs network gives clients access to the firm's sectored block trades and their insights into price discovery. Their electronic trading program provides clients with tools to manage their trades from pre-trade analytics to post-trade analysis. | Financial Conglomerates | Corporate Officer/Principal Corporate Officer/Principal | |
| University of Oxford | College/University | Undergraduate Degree Corporate Officer/Principal | |
| University of Cambridge | College/University | Doctorate Degree Corporate Officer/Principal Undergraduate Degree Graduate Degree | |
Atlas Venture Advisors, Inc.
 Atlas Venture Advisors, Inc. Investment ManagersFinance Atlas Venture Advisors Inc (Atlas Venture Advisors) is a venture capital firm founded in 1980 by Christopher Julian Spray. The firm is headquartered in Cambridge, Massachusetts. | Investment Managers | Corporate Officer/Principal Consultant / Advisor Consultant / Advisor Consultant / Advisor | |
| University of London | College/University | Doctorate Degree Undergraduate Degree | |
| INSEAD | College/University | Director/Board Member Masters Business Admin Masters Business Admin | |
| University of California, Berkeley | College/University | Undergraduate Degree General Counsel | |
| Trinity College Dublin | College/University | Masters Business Admin Corporate Officer/Principal Doctorate Degree | |
| FINANCIÈRE DE TUBIZE S.A. | Financial Conglomerates | Director/Board Member Director/Board Member Director/Board Member Director/Board Member | |
| University of Geneva | College/University | Undergraduate Degree Graduate Degree Doctorate Degree Corporate Officer/Principal | |
| Swiss Federal Institute of Technology | College/University | Doctorate Degree Corporate Officer/Principal | |
European Federation of Pharmaceutical Industries & Assns
 European Federation of Pharmaceutical Industries & Assns Miscellaneous Commercial ServicesCommercial Services The European Federation of Pharmaceutical Industries & Assns is a trade association that promotes pharmaceutical discovery and development. The non-profit company is based in Brussels, Belgium. | Miscellaneous Commercial Services | Director/Board Member Director/Board Member Director/Board Member | |
Novartis Institutes for Biomedical Research, Inc.
 Novartis Institutes for Biomedical Research, Inc. Miscellaneous Commercial ServicesCommercial Services Novartis Institutes for Biomedical Research, Inc. conducts biomedical researches. It focuses in the areas of oncology, ophthalmology, diabetes, musculoskeletal disorders, neuroscience, and cardiovascular conditions, other focus areas include discovery chemistry, biologics, pathway biology, and translational medicine. The company was founded on September 10, 2002 and is headquartered in Cambridge, MA. | Miscellaneous Commercial Services | Chief Tech/Sci/R&D Officer Director/Board Member Corporate Officer/Principal | |
| AKEBIA THERAPEUTICS, INC. | Pharmaceuticals: Major | Director/Board Member Corporate Officer/Principal | |
Altimmune UK Ltd.
 Altimmune UK Ltd. BiotechnologyHealth Technology Altimmune UK Ltd. engages in the discovery and development of prophylactic and therapeutic vaccines against mutating viruses and cancer. It provides T-cell vaccines to protect patients against infectious diseases (most notably mutating viruses) and to treat cancers; and Flunisyn, a DepoVaccine to protect against influenza. The company was founded by Bertrand Georges in 2003 and is headquartered in London, the United Kingdom. | Biotechnology | Director/Board Member Director/Board Member | |
Keystone Symposia
 Keystone Symposia Miscellaneous Commercial ServicesCommercial Services Keystone Symposia operates as a catalyst for the advancement of biomedical and life sciences by connecting scientists within and across disciplines at conferences and workshops. The company was founded by C. Fred Fox in 1972 and is headquartered in Silverthorne, CO. | Miscellaneous Commercial Services | Director/Board Member Director/Board Member | |
| MERUS N.V. | Biotechnology | Director/Board Member Director/Board Member | |
UCB Fipar SA
 UCB Fipar SA Financial ConglomeratesFinance Part of UCB SA, UCB Fipar SA is an investment holding Belgian company. The private company is based in Anderlecht, Belgium. UCB Fipar was founded in 1947. | Financial Conglomerates | Director/Board Member Director/Board Member | |
MyoPowers Medical Technologies France SAS
 MyoPowers Medical Technologies France SAS Medical SpecialtiesHealth Technology MyoPowers Medical Technologies France SA operates as a medical device company. It specializes in muscle technologies to restore or improve muscle function. The firm also develops implantable medical devices for the treatment of severe stress urinary incontinence. The company was founded by Piergiorgio Tozzi and Daniel Hyoz in June 2004 and is headquartered in Lausanne, Switzerland. | Medical Specialties | Director/Board Member Director of Finance/CFO | |
Opsona Therapeutics Ltd.
 Opsona Therapeutics Ltd. Pharmaceuticals: MajorHealth Technology Opsona Therapeutics Ltd. operates as a immunology drug development company. It focuses on novel therapeutics and specializes in the prevention and treatment of solid organ transplantation, cancer, diabetes, autoimmune, inflammatory and Alzheimer’s diseases. The firm developed OPN-305, an antibody to reduce pro-inflammatory cytokine production, which is now at the clinical testing phase. The company was founded by Luke O'Neill, Kingston Mills and Dermot Kelleher in 2004 and is headquartered Dublin, Ireland. | Pharmaceuticals: Major | Director/Board Member Chairman | |
AstraZeneca LP
 AstraZeneca LP Pharmaceuticals: MajorHealth Technology Part of AstraZeneca PLC, AstraZeneca LP is a pharmaceutical company that focuses on developing and commercializing prescription drugs for various therapeutic areas. The private company is based in Wilmington, DE. | Pharmaceuticals: Major | Corporate Officer/Principal Private Equity Investor | |
Lumos Pharma Sub, Inc.
 Lumos Pharma Sub, Inc. Medical/Nursing ServicesHealth Services Lumos Pharma Sub, Inc. develops and commercializes a novel treatment for the rare disease creatine transporter deficiency. It focuses on bringing novel therapies to patients afflicted with unmet medical needs in severe, rare, and genetic diseases. The firm's technology LUM-001 is a repurposed small molecule that is a kinetically similar analog of creatine and has shown promising therapeutic potential for the treatment of creatine transporter deficiency. Lumos Pharma was founded by Richard J. Hawkins in 2010 and is headquartered in Austin, TX. | Medical/Nursing Services | Director/Board Member Director/Board Member | |
Syncona Partners LLP
 Syncona Partners LLP Investment ManagersFinance Syncona Partners LLP (Syncona Partners) is a venture capital subsidiary of Syncona Investment Management Ltd. founded in 2012 by Martin Murphy. The firm is headquartered in London, United Kingdom. | Investment Managers | Chief Executive Officer Private Equity Investor | |
| Harvard Business School | College/University | Masters Business Admin Masters Business Admin Masters Business Admin | |
Synlogic Operating Co., Inc.
 Synlogic Operating Co., Inc. Pharmaceuticals: MajorHealth Technology Synlogic Operating Co., Inc. operates as a biopharmaceutical company. The firm's pipeline focuses on rare diseases, the company is leveraging the broad potential of its synthetic biotics platform for novel drug development in major disease areas through partnerships with pharmaceutical and biotechnology companies. It also engages in development of synthetic biotics-based treatment for inflammatory bowel disease. The company was founded by James J. Collins and Timothy K. Lu in 2014 and is headquartered in Cambridge, MA. | Pharmaceuticals: Major | Director/Board Member Chief Executive Officer | |
Blue Earth Diagnostics Ltd.
 Blue Earth Diagnostics Ltd. Medical/Nursing ServicesHealth Services Blue Earth Diagnostics Ltd. engages in the development and commercialization of positron emission tomography imaging agents. It focuses on the molecular imaging diagnostics. The company was founded in March 2014 and is headquartered in Oxford, the United Kingdom. | Medical/Nursing Services | Chairman Director/Board Member | |
Oculis SA
 Oculis SA Miscellaneous Commercial ServicesCommercial Services Oculis SA focuses on ophthalmic drugs and novel drug delivery to the eye. The Oculis drug delivery platform consists of a novel technique to facilitate drug absorption to both anterior and posterior parts of the eye. The advantage is a drug delivery system where diseases of the posterior part of the eye can be treated with a simple topical application. The Oculis drug delivery platform allows diseases such as DME (diabetic macular edema) at the posterior part of the eye to be treated with a non-invasive topical application. The company was founded by Einar Stefansson and Thorsteinn Loftsson in 2003is headquartered in Pully, Switzerland. | Miscellaneous Commercial Services | Director/Board Member Director/Board Member Chairman | |
Achilles Therapeutics UK Ltd.
 Achilles Therapeutics UK Ltd. BiotechnologyHealth Technology Achilles Therapeutics Ltd. operates as a biopharmaceutical company. The firm develops personalized vaccines and adoptive T cell therapies to treat metastatic cancer. It uses DNA sequencing data from each patient, together with a proprietary bioinformatics platform, to identify clonal neoantigens specific to that patient and enable the development of personalised cell therapies. The company was founded by Karl Peggs, Mark Lowdell, Charles Swanton and Sergio Quezada in May 2016 and is headquartered in London, the United Kingdom. | Biotechnology | Director/Board Member Corporate Officer/Principal | |
Cerevance, Inc.
 Cerevance, Inc. Medical SpecialtiesHealth Technology Cerevance, Inc. provides pharmaceutical services. The firm discovers new treatments for central nervous system diseases. Its platform enables to profile specific brain cell types including both neurons and glial cells in mature human brain tissue. The company was founded by Bradley A. Margus and Mark Carlton in 2016 and is headquartered in Boston, MA. | Medical Specialties | Director/Board Member Director/Board Member | |
| INOZYME PHARMA, INC. | Pharmaceuticals: Major | Chief Executive Officer Director/Board Member | |
| BLACK DIAMOND THERAPEUTICS, INC. | Biotechnology | Director/Board Member Investor Relations Contact | |
Priothera SAS
 Priothera SAS BiotechnologyHealth Technology Part of Priothera Ltd., Priothera SAS is a French company dedicated to improving the lives of patients suffering from hematological malignancies by delivering an innovative immune modulator to enhance the curative potential of both allogeneic hematopoietic stem cell transplantation (HSCT) and CAR-T cell therapy. The private company is based in Saint-Louis, France. Priothera is leading the way in developing Mocravimod, a S1P receptor modulator as an adjunctive and maintenance immune therapy to allo-HSCT and to CAR-T. Mocravimod has the potential to reduce the occurrence of (acute) GVHD without suppressing T cell function, thus GVL is maintained. Priothera is developing Mocravimod (KRP203) to significantly improve the clinical outcome of allo-HSCT and CAR-T therapy. The company was founded in 2020 by Philippe Lievre, Florent Gros, Brice R. Suire, Stephan Oehen, Simone Seiter. Florent Gros has been the CEO since 2020. | Biotechnology | Chief Executive Officer Founder Founder Founder | |
RA Capital Management LP (Private Equity)
 RA Capital Management LP (Private Equity) Investment ManagersFinance RA Capital Management LP (Private Equity) (RA Capital) is a private equity & venture capital subsidiary of RA Capital Management LP founded by Peter Kolchinsky in 2004. The firm is headquartered in Boston, MA. | Investment Managers | Private Equity Investor Private Equity Investor | |
Clade Therapeutics, Inc.
 Clade Therapeutics, Inc. BiotechnologyHealth Technology Clade Therapeutics, Inc. is a company that aims to discover and deliver next-generation cell medicines to improve the lives of patients in need. Clade Therapeutics is based in Boston, MA. The company is initially focused on harnessing the potential of "cloaked" immune cells for cancer treatment. Clade Therapeutics is led by a world-class team of company builders and scientific innovators with unparalleled expertise in generating stem cell-derived adult T, NK, and B cells. The company is supported by a premier investor syndicate, including Lifesci Venture Partners, Emerson Collective, and Bristol-Myers Squibb. The company was founded by Jim Glasheen, Deepta Bhattacharya, Chris Sturgeon, Gustavo Mostoslavsky, Leandro Vetcher, Chad Cowan, and Chad Cowan has been the CEO since incorporation. | Biotechnology | Chairman Director/Board Member | |
Inversago Pharma, Inc.
 Inversago Pharma, Inc. Pharmaceuticals: MajorHealth Technology Inversago Pharma, Inc. develops novel gastrointestinal drugs. The company was founded by Fran?ois Ravenelle in and is headquartered in Montreal, Canada. | Pharmaceuticals: Major | Director/Board Member Director/Board Member | |
Vivet Therapeutics SAS
 Vivet Therapeutics SAS BiotechnologyHealth Technology Vivet Therapeutics SAS develops novel gene therapy treatments for inherited metabolic diseases. The firm offers its services under the categorizers of Biopharma, Biotechnology and Health Care. The company was founded by Jean-Philippe Combal, Gloria Gonzalez-Aseguinolaza and Jens Kurth on July 26, 2016 and is headquartered in Paris, France. | Biotechnology | Chairman Director/Board Member | |
Neogene Therapeutics, Inc.
 Neogene Therapeutics, Inc. BiotechnologyHealth Technology Neogene Therapeutics, Inc. engages in the provision T cell therapies to treat cancer. The company was founded by Ton N. M. Schumacher and Carsten Linnemann and is headquartered in New York, NY. | Biotechnology | Director/Board Member Director/Board Member | |
| SYNLOGIC, INC. | Biotechnology | Director/Board Member Chief Executive Officer |
Statistieken
Internationaal
| Verenigde Staten | 25 |
| Zwitserland | 8 |
| Verenigd Koninkrijk | 8 |
| Frankrijk | 5 |
| België | 4 |
Sectoraal
| Health Technology | 27 |
| Consumer Services | 10 |
| Commercial Services | 7 |
| Finance | 7 |
| Health Services | 4 |
Operationeel
| Director/Board Member | 512 |
| Corporate Officer/Principal | 188 |
| Independent Dir/Board Member | 119 |
| Chairman | 83 |
| Chief Executive Officer | 72 |
Sterkste connecties
| Insiders | |
|---|---|
| Ed Mathers Mathers | 47 |
| Thomas Woiwode | 39 |
| Martin Murphy | 33 |
| Sandrine Dufour | 29 |
| Henry Skinner | 29 |
| Florent Gros | 28 |
| Lionel Carnot | 27 |
| Ulf Arne Wiinberg | 26 |
| William Kane | 26 |
| Nilesh Kumar | 26 |
| Albrecht de Graeve | 25 |
| Daniel Vasella | 25 |
| Thomas Dyrberg | 24 |
| Stefan Oschmann | 23 |
| Jan Berger | 22 |
- Beurs
- Insiders
- Dhavalkumar Patel
- Bedrijfsconnecties
